OS Therapies Inc
ostherapies.comWhat Do They Do?
Develops cancer immunotherapies and antibody-drug conjugates for osteosarcoma and other solid tumors, including cancers affecting children and young adults.
10-K for FY2025, filed Mar 31, 2026OS Therapies Incorporated (“OS Therapies,” the “Company,” “we,” “our” or “us”) is a clinical stage biopharmaceutical company focused on the…View ↗
We also own rights to an OST-Tunable Drug Conjugate (OST-tADC) platform, a next generation antibody-drug conjugate (ADC) silicone dioxide…View ↗
We have built a pipeline of product candidates targeting multiple indications for solid cancers. Our pipeline includes two drug…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$8.6MView ↗
- ▲ +90% (Loss)
- vs −$4.5M in Q2 FY2025
Who Do They Compete With?
Competes with AstraZeneca and Y-mAbs Therapeutics
10-K for FY2025, filed Mar 31, 2026While we are not currently aware of any adjuvant therapy for Osteosarcoma intended for use in pediatric patients that is further advanced…View ↗
Loading...
